Abeona Therapeutics Inc
ABEO6.420USD
-0.070-1.08%
收盘 08/04, 16:00（美东）报价延迟15分钟
314.28M总市值
亏损市盈率 TTM
关于 Abeona Therapeutics Inc 公司
Abeona Therapeutics Inc. 是一家临床阶段的生物制药公司。该公司致力于开发危及生命的疾病的细胞和基因疗法。该公司的主要临床项目是 prademagene zamikeracel (pz-cel)，这是其研究性自体 COL7A1 基因校正表皮片，目前正在开发用于治疗隐性营养不良性大疱性表皮松解症 (RDEB)。该公司完全集成的细胞和基因治疗良好生产规范 (cGMP) 制造设施是其 III 期 VIITAL 试验中使用的 pz-cel 的生产基地，能够在 FDA 批准后支持 pz-cel 的商业化生产。该公司的开发组合还包括基于腺相关病毒 (AAV) 的基因疗法，用于治疗具有高度未满足医疗需求的眼科疾病。该公司的新型下一代 AAV 衣壳正在接受评估，以改善各种毁灭性疾病的趋向性特征。
公司简介
公司代码ABEO
公司名称Abeona Therapeutics Inc
上市日期Sep 19, 1980
CEODr. Vishwas (Vish) Seshadri, Ph.D.
员工数量136
证券类型Ordinary Share
年结日Sep 19
公司地址6555 Carnegie Ave, 4th Floor
城市CLEVELAND
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编44103
电话16468134701
网址https://abeonatherapeutics.com/
公司代码ABEO
上市日期Sep 19, 1980
CEODr. Vishwas (Vish) Seshadri, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.23M
-5.32%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
180.47K
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
154.37K
--
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
145.44K
-3.44%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
120.48K
-9.80%
Mr. Mark J. Alvino
Mr. Mark J. Alvino
Independent Director
Independent Director
77.34K
-14.48%
Dr. Bernhardt G. Zeiher, M.D.
Dr. Bernhardt G. Zeiher, M.D.
Independent Director
Independent Director
47.15K
--
Dr. Eric Crombez, M.D.
Dr. Eric Crombez, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph Vazzano, CPA
Mr. Joseph Vazzano, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Faith L. Charles, J.D.
Ms. Faith L. Charles, J.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.23M
-5.32%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
180.47K
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
154.37K
--
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
145.44K
-3.44%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
120.48K
-9.80%
Mr. Mark J. Alvino
Mr. Mark J. Alvino
Independent Director
Independent Director
77.34K
-14.48%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月12日 周六
更新时间: 7月12日 周六
持股股东
股东类型
持股股东
持股股东
占比
Suvretta Capital Management, LLC
7.20%
Nantahala Capital Management, LLC
6.86%
Adage Capital Management, L.P.
5.26%
Western Standard, LLC
4.46%
The Vanguard Group, Inc.
3.95%
Other
72.27%
持股股东
持股股东
占比
Suvretta Capital Management, LLC
7.20%
Nantahala Capital Management, LLC
6.86%
Adage Capital Management, L.P.
5.26%
Western Standard, LLC
4.46%
The Vanguard Group, Inc.
3.95%
Other
72.27%
股东类型
持股股东
占比
Hedge Fund
39.27%
Investment Advisor
9.65%
Investment Advisor/Hedge Fund
6.04%
Individual Investor
5.83%
Venture Capital
4.82%
Research Firm
3.12%
Pension Fund
0.17%
Other
31.08%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
154
35.41M
69.26%
-4.09M
2025Q1
147
35.53M
69.67%
-3.94M
2024Q4
142
35.48M
81.61%
-1.29M
2024Q3
136
33.53M
77.24%
-4.39M
2024Q2
136
35.81M
86.04%
+12.73M
2024Q1
132
18.43M
63.48%
+1.42M
2023Q4
122
17.76M
63.56%
+2.13M
2023Q3
129
13.60M
55.05%
-1.35M
2023Q2
141
10.67M
49.73%
+4.50K
2023Q1
170
7.90M
44.30%
-1.15M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Suvretta Capital Management, LLC
3.69M
7.2%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
3.51M
6.86%
-19.36K
-0.55%
Mar 31, 2025
Adage Capital Management, L.P.
2.69M
5.26%
-1.21M
-31.03%
Mar 31, 2025
Western Standard, LLC
2.28M
4.46%
+196.78K
+9.44%
Mar 31, 2025
The Vanguard Group, Inc.
2.02M
3.95%
+54.16K
+2.75%
Mar 31, 2025
Vivo Capital, LLC
1.84M
3.6%
--
--
Mar 31, 2025
Rosalind Advisors, Inc.
1.81M
3.53%
+427.00
+0.02%
Mar 31, 2025
Laurion Capital Management LP
1.31M
2.55%
--
--
Mar 31, 2025
Armistice Capital LLC
1.30M
2.54%
+1.30M
--
Dec 31, 2023
Seshadri (Vishwas)
1.30M
2.55%
-51.56K
-3.80%
Jun 06, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Simplify Propel Opportunities ETF
4.69%
iShares Neuroscience and Healthcare ETF
0.63%
iShares Micro-Cap ETF
0.06%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
查看更多
Simplify Propel Opportunities ETF
占比4.69%
iShares Neuroscience and Healthcare ETF
占比0.63%
iShares Micro-Cap ETF
占比0.06%
iShares Russell 2000 Growth ETF
占比0.02%
Proshares Ultra Russell 2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
iShares Russell 2000 ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
公告日期
类型
比率
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
